
Excellent overview, David! 👏 @Dr_Aggen For me, switching ADC targets and payloads is among the most promising strategies after EV+pembrolizumab failure—alongside novel mechanisms such as radioligand therapies (RLTs) and T-cell engagers (TCEs). But a key biological question remains: Is NECTIN4 still a valid target after EV resistance? In NEXUS, EV-pretreated patients showed lower response rates than EV-naïve patients—a signal worth investigating further, although prior EV exposure does not necessarily imply loss of NECTIN4. There are so many potentially actionable cell-surface targets in urothelial cancer, many still largely unexplored. We need to understand both primary and acquired resistance biology to guide the next treatment, rather than simply switch drugs. 🧬 @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3 x.com/dr_aggen/status/212237…






















